171 related articles for article (PubMed ID: 22555806)
1. EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target.
Xiao Z; Carrasco R; Kinneer K; Sabol D; Jallal B; Coats S; Tice DA
Cancer Biol Ther; 2012 Jun; 13(8):630-7. PubMed ID: 22555806
[TBL] [Abstract][Full Text] [Related]
2. EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells.
Kim I; Ryu YS; Kwak HJ; Ahn SY; Oh JL; Yancopoulos GD; Gale NW; Koh GY
FASEB J; 2002 Jul; 16(9):1126-8. PubMed ID: 12039842
[TBL] [Abstract][Full Text] [Related]
3. Ephrin B2/EphB4 pathway in hepatic stellate cells stimulates Erk-dependent VEGF production and sinusoidal endothelial cell recruitment.
Das A; Shergill U; Thakur L; Sinha S; Urrutia R; Mukhopadhyay D; Shah VH
Am J Physiol Gastrointest Liver Physiol; 2010 Jun; 298(6):G908-15. PubMed ID: 20338920
[TBL] [Abstract][Full Text] [Related]
4. Ephrin type-B receptor 4 activation reduces neointimal hyperplasia in human saphenous vein in vitro.
Wong DJ; Lu DY; Protack CD; Kuwahara G; Bai H; Sadaghianloo N; Tellides G; Dardik A
J Vasc Surg; 2016 Mar; 63(3):795-804. PubMed ID: 25446283
[TBL] [Abstract][Full Text] [Related]
5. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.
Kumar SR; Singh J; Xia G; Krasnoperov V; Hassanieh L; Ley EJ; Scehnet J; Kumar NG; Hawes D; Press MF; Weaver FA; Gill PS
Am J Pathol; 2006 Jul; 169(1):279-93. PubMed ID: 16816380
[TBL] [Abstract][Full Text] [Related]
6. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
[TBL] [Abstract][Full Text] [Related]
7. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway.
Noren NK; Foos G; Hauser CA; Pasquale EB
Nat Cell Biol; 2006 Aug; 8(8):815-25. PubMed ID: 16862147
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor-A inhibits EphB4 and stimulates delta-like ligand 4 expression in adult endothelial cells.
Yang C; Guo Y; Jadlowiec CC; Li X; Lv W; Model LS; Collins MJ; Kondo Y; Muto A; Shu C; Dardik A
J Surg Res; 2013 Jul; 183(1):478-86. PubMed ID: 23394931
[TBL] [Abstract][Full Text] [Related]
9. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.
Aslam MI; Abraham J; Mansoor A; Druker BJ; Tyner JW; Keller C
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6383-8. PubMed ID: 24733895
[TBL] [Abstract][Full Text] [Related]
10. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor.
Noren NK; Yang NY; Silldorff M; Mutyala R; Pasquale EB
Biochem J; 2009 Aug; 422(3):433-42. PubMed ID: 19552627
[TBL] [Abstract][Full Text] [Related]
11. Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells.
Füller T; Korff T; Kilian A; Dandekar G; Augustin HG
J Cell Sci; 2003 Jun; 116(Pt 12):2461-70. PubMed ID: 12734395
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of the Ras-mitogen-activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrin-induced neurite retraction.
Elowe S; Holland SJ; Kulkarni S; Pawson T
Mol Cell Biol; 2001 Nov; 21(21):7429-41. PubMed ID: 11585923
[TBL] [Abstract][Full Text] [Related]
13. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA
Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689
[TBL] [Abstract][Full Text] [Related]
14. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth.
Kertesz N; Krasnoperov V; Reddy R; Leshanski L; Kumar SR; Zozulya S; Gill PS
Blood; 2006 Mar; 107(6):2330-8. PubMed ID: 16322467
[TBL] [Abstract][Full Text] [Related]
15. Targeting receptor tyrosine kinase EphB4 in cancer therapy.
Chen Y; Zhang H; Zhang Y
Semin Cancer Biol; 2019 Jun; 56():37-46. PubMed ID: 28993206
[TBL] [Abstract][Full Text] [Related]
16. EphrinB2/EphB4 Signaling Regulates DPSCs to Induce Sprouting Angiogenesis of Endothelial Cells.
Gong T; Xu J; Heng B; Qiu S; Yi B; Han Y; Lo ECM; Zhang C
J Dent Res; 2019 Jul; 98(7):803-812. PubMed ID: 31017515
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism of inhibition of the abnormal proliferation of human umbilical vein endothelial cells by hydroxysafflor-yellow A.
Wang J; Wang J; Wang X; Liu L; Hu J; Yu X; Xu Y; Niu X; Lin Z; Zhang Y; Zhang X; Zhang Q
Pharm Biol; 2016 Sep; 54(9):1800-7. PubMed ID: 26730646
[TBL] [Abstract][Full Text] [Related]
18. Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease.
Piffko A; Broggini T; Harms C; Adams RH; Vajkoczy P; Czabanka M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360793
[TBL] [Abstract][Full Text] [Related]
19. EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis.
Huang X; Yamada Y; Kidoya H; Naito H; Nagahama Y; Kong L; Katoh SY; Li WL; Ueno M; Takakura N
Cancer Res; 2007 Oct; 67(20):9800-8. PubMed ID: 17942910
[TBL] [Abstract][Full Text] [Related]
20. EphB4 promotes site-specific metastatic tumor cell dissemination by interacting with endothelial cell-expressed ephrinB2.
Héroult M; Schaffner F; Pfaff D; Prahst C; Kirmse R; Kutschera S; Riedel M; Ludwig T; Vajkoczy P; Graeser R; Augustin HG
Mol Cancer Res; 2010 Oct; 8(10):1297-309. PubMed ID: 21047731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
